ULTRAGENYX PHARMACEUTICAL INC financial statements, including revenue, expenses, profit, and loss
The total revenue of RARE for the last quarter is 1.80 B MXN, and it's 16.64% lower compared to the previous quarter. The net income of Q1 24 is -2.83 B MXN.